AML-437: Survival of Patients with Secondary Acute Myeloid Leukemia in a University Hospital in Colombia

Abstract

Context: Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Objective: To determine the OS of patients diagnosed with AML according to the type of AML, de novo (n-AML) or secondary (s-AML), in the Clinica Foscal, a university hospital in Colombia during 2013–2020. Results: A total of 157 patients were registered; 50.3% were male; the median age at the time of diagnosis was 58.8 years (range: 18–95); for n-AML median age was 57.4 years (range: 18–95), and 62.3 years (range: 26–84) for s-AML. Regarding the etiology of AML, 75.2% presented n-AML and 24.8% s-AML, distributed as follows: 23.1% secondary to chronic myeloproliferative neoplasms, 10.3% to therapy, and 4% to myelodysplasia. In patients with n-AML, 74.3% were classified as ECOG Conclusions: Our results demonstrated worse outcomes for patients with s-AML compared with patients with n-AML. It is important to identify s-AML patients and review their genetic and molecular expressions, so a directed treatment can be offered with major effectivity and early allogeneic transplant.